🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Hong Jae Chon

CHA University Bundang Medical Center

ORCID: 0000-0002-6979-5812

Also affiliated with CHA University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study”.

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

European Journal of Cancer(2022)10.1016/j.ejca.2022.08.024

N/A

0DataRank · unranked

112 citations

Jaekyung Cheon, Antonio D’Alessio, Naoshi Nishida, Celina Ang, Thomas U. Marron +32 more

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Hepatology Communications(2023)10.1097/hc9.0000000000000302

N/A

0DataRank · unranked

11 citations

Bernhard Scheiner, Antonio D ́Alessio, Claudia Angela Maria Fulgenzi, Martin Schönlein, Lorenz Kocheise +31 more

111P The concordance between circulating tumor DNA and tissue genomic profiling in patients with advanced biliary tract cancer

Annals of Oncology(2023)10.1016/j.annonc.2023.09.1404

N/A

0DataRank · unranked

0 citations

Soyoon Hwang, G. Kim, Hyunwoo P. Kang, Dong Soo Kyung, Wonsup Lee +5 more

Clinical Feasibility of Circulating Tumor DNA in Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

Liver Cancer(2025)10.1159/000549565

N/A

0DataRank · unranked

2 citations

Dong Jun Shin, Beodeul Kang, Haeyoun Kang, Sung Hwan Lee, Jung Sun Kim +10 more